New Alzheimer's drug takes first step in patients
Symptom relief
Recruiting now
This study tests a new drug called THN391 in 15 people with early Alzheimer's disease to see if it is safe and how the body handles it. Participants will receive three monthly doses of the drug or a placebo and undergo blood tests, brain scans, spinal taps, and memory tests. This…
Phase: PHASE1 • Sponsor: Therini Bio, Inc. • Aim: Symptom relief
Last updated May 18, 2026 12:01 UTC